4582 SymBio Pharmaceuticals
- 252
- +4+1.61%
SymBio Pharmaceuticals News
Emerging market outlook: Will the Growth Market 250 Index take a break and individual stock picking strengthen with positive investor sentiment?
■ The emerging market this week has seen a significant increase in overall market conditions, with major stocks showing strength. During the same period, while the Nikkei Average increased by +0.79%, the Growth Market Index rose by +4.63% and the Growth Market 250 Index rose by +5.16%, highlighting the growth of the emerging market. Similar to the main board, trading volume has not expanded significantly, but driven by improved investor sentiment, major stocks with large market capitalization, such as constituents of the Growth Market Core Index, have shown overall strength. The Growth Market 250 Index opened on August 1st.
Part 2 of the previous day's moving stocks include M&A SOKO Holdings, Sakura Internet, Big Camera, etc.
Stock name (code) 20-day closing price ⇒ Previous day comparison Kitagawa Seiki <6327> 723-48. June 2015 operating profit is expected to decrease by 38%. MonotaRO <3064> 2,458.5-7. Sell off profits against the recent rise continues. Neo Marketing <4196> 1107 +20 Release a beta version of the new interview service "Chat AI Research DEMO!" that takes advantage of the latest AI technology. M&A Consulting Holdings <9552> 2785
Shin Bio Pharmaceutical initiates international collaborative phase 1b clinical trial targeting patients with malignant lymphoma with injection Brincidofovir.
On the 19th, Shionogi Pharmaceutical Co., Ltd. <4582> announced that it has submitted a clinical trial plan to the Pharmaceuticals and Medical Devices Agency on August 5, 2024 for an injection drug, Brincidofovir (IV BCV), for relapsed or refractory lymphoma patients (malignant lymphoma such as NK/T-cell lymphoma), and has started the Phase 1b/2 international clinical trial. The company has been conducting joint research on BCV with the Singapore National Cancer Centre, and in non-clinical trials of BCV...
Recommended stocks based on volume changes, including Seven Bank and others.
Stock Closing Price Change from Previous Day Volume*<2639> GX Bio & Med Day Stock 1672 1 6421*<8410> Seven Bank 288.9 22.1 39716200*<4582> Shionogi Pharma 320 80 20844500*<2841> IF NASDAQ 100 H Share 12650 495 95137
Stocks that moved the previous day, part 1: 7&iHD, Shionogi & Co., Ltd., Double A, etc.
Stock name <code>19 closing price ⇒ comparison with the previous dayAsuka Pharmaceutical HD <4886> 2,309 + 21 Obtained approval for manufacturing and selling oral contraceptive drospirenone in South Korea. In the afternoon, the increase narrowed. 7&iHD <3382> 2,161 + 400 Acquired proposal reported from Canada's largest convenience store chain, Alimentation Couche-Tard. Renascience <4889> 353 + 14 Clinical performance tests of AI to predict insulin dosage for diabetes patients have started. Economic <3802>
The Tokyo Stock Exchange Growth Market Index has risen for 9 consecutive days, showing relative stability.
Tokyo Stock Exchange Growth Market Index 786.35 +2.40 / volume 0.3533 billion shares / trading value 139 billion yen Tokyo Stock Exchange Growth Market 250 Index 612.03 +2.92 /volume 0.2502 billion shares / trading value 111.4 billion yen Today's growth market, the Tokyo Stock Exchange Growth Market Index has risen for 9 consecutive days, and the Tokyo Stock Exchange Growth Market 250 Index has also risen. The number of rising stocks is 206, the number of falling stocks is 348, and unchanged is 34. On the 16th, the Dow Jones Industrial Average rose 96.70 dollars to 40659.
Active and newly established stocks in the afternoon session.
*Asuka Pharmaceutical HD <4886> 2309 + 21 has obtained approval for manufacturing and sales of the oral contraceptive Drospirenone in South Korea. In the afternoon, the increase narrowed. *7 & i HD <3382> 2161 + 400 reported acquisition proposal from Canadian convenience store giant Alimentation Couche-Tard. *Renascience <4889> 353 + 14 clinical performance tests of AI predicting insulin dosage for diabetic patients has started. *Economic <3802> 435 + 15100 shares or more.
Stocks hitting the upper or lower price limit in the afternoon session.
Stop limit up: Astroscale Holdings (206A), PRISM BioLab (2743), Pixel Companies (3358), YS Food (3382), Seven & I Holdings (4197), Asmark (4582), Shin Nippon Biomedical Laboratories (4894), Qualiphi (6836), Plathome (7044), Piala. Stop limit down: Birdman (7063). (Includes temporary limit up and limit down (indication value).)
Emerging market stock digest: Astroscale, Shinbio Pharmaceutical hit the limit.
<186A> Astro Scale Co., Ltd. rose by 150 points to 934, having announced to have signed a large contract for JAXA's (Japan Aerospace Exploration Agency) Commercial Removal of Debris Demonstration (CRD2) Phase II through subsidiary Astro Scale. The contract amount is JPY 1.2 billion (excluding tax) and the contract period will be until the end of March 29. The income has been priced in for the full year consolidated financial estimates for the year ending in April 2025 (project income), but it will be recognized over the contract period.
Volume change rate ranking (10 o'clock) ~ Panpasi HD, JTOWER and others ranked.
In the volume change rate ranking, by comparing the volume of the latest 5 days and the volume of the delivery day, we can understand the interests of market participants such as the trend of material selection. Top volume change rate [As of 10:32 on August 19] (comparison of the latest 5-day average volume) Stock code, stock name, volume, 5-day average volume, volume change rate, and stock price change rate: <4485> JTOWER 1823300 315508.28 329.05% 0.6
Volume change rate ranking (13:00) - Come Hime HD, Life Drink, etc. rank in.
*In the volume change rate ranking, comparing the volume of the last 5 average days and the volume of the delivery day can reveal the interest of market participants such as stock picking trends. *Top Volume Change Rate [as of August 14, 13:32] (compared to the last 5-day average volume) Code => Stock Name => Volume => 5-day Average Volume => Volume Change Ratio => Stock Price Change Ratio <6562> Genie 823,000 73,027.44 288.22% 0.0133% <3271> Glo
Ranking of Volume Change Rate (9:00) - Kenko Mayonnaise, Oxide, etc. are ranked.
In the volume change rate rankings, by comparing the volume of the last 5 days to the volume on the day of distribution, market participants can understand trends in market interest. Top volume change rate [as of 9:32 am on August 7] (comparison of average volume of the last 5 days): Code, Stock Name, Volume, 5-day average volume, Volume change rate, Stock price change rate <6521> Oxide 204,500 107,185.08 110.9% -0.1711.
Part 2 of the stocks that moved the day before include Kasumigaseki Capital, Tokyo Marine Holdings, Nintendo Co Ltd, etc.
Company name <Code> 5-day closing price ⇒ compared to the previous day FukuoKa FG＜8354＞ 3217 -700 selling regional bank stocks. Tokyo Marine HD＜8766＞ 4046 -1000 Insurance stocks had the second highest decline rate after the banking sector. Kasumigaseki Capital＜3498＞ 7950 -3000 Concerns about the impact of domestic interest rate hikes are looming. T & DH＜8795＞ 2046 -459 Insurance stocks are also sold due to the decline in long-term US interest rates. Mitsui E & S＜7003＞ 843 -300 Worsening market conditions.
Stocks that moved the day before part 2: Japan Electric, Japan Steel Works, Laser Tech, etc.
Stock Name <Code> 2-day closing price ⇒ day-on-day comparison: Mitsui Chemicals <4183> 3811 -411, trouble occurred at a subsidiary's ethylene plant. NEC <6701> 11325 -1520, possible impact of the drop in U.S. high-tech stocks. Nippon Steel <5631> 3708 -392, pushed down by the worsening market conditions without specific material observations. Laser Tech <6920> 22600 -2740, main semiconductor manufacturing equipment stocks under significant pressure due to drop in U.S. semiconductor stocks. Mitsubishi UFJ FG <8306>
Emerging Market Stock Digest: BS rises opposite, Shin Nippon Biomedical Laboratories falls significantly.
<7776> Cellseed 566 +24 continued to rise. Trading has become active due to the Tokyo Stock Exchange lifting the temporary credit trading measures from July 30th, and it continues to rise today. TSE had implemented regulations that commission margins for selling and buying new credit trading assets should be 50% or more (including cash of 20% or more). Japan Securities Finance has also lifted its additional collateral collection measures. <4883> Modaris 134 -9 significant decline. On August 2, Mr. Nuregi submitted his finances.
SymBio Pharmaceuticals: Confirmatory letter.
SymBio Pharmaceuticals: Semiannual Report - 20th Period (01/01/2024 - 12/31/2024)
Active and newly listed stocks during the morning session.
*JVC Kenwood (6632) rose 150 to 1,010, with expectations heightened for exceeding performance for Q1, which showed a significant increase in earnings beyond expectations. *Nippon Ham (2282) rose 367 to 5,090, with significant improvement in performance in Australia and other countries beyond expectations in Q1. *M&A Consulting (9552) announced the implementation of the buyback of its own stock. *Konami Group (9766) showed a significant increase in earnings beyond market expectations for Q1, with a rise of 655 to 11,760. *Sumitomo Electric Industries (5802) was up 35 to 2,254.5 for the fiscal year.
Hot stocks digest (morning session): JVCKW, Toko Electric, Nippon Ham, etc.
Toshiba Electronic's stock price dropped significantly to ¥27,235 (-¥3,505). Other semiconductor giants like KOKUSAI and SCREEN also saw declines. The US economy is facing concerns of a recession due to worse than expected ISM manufacturing index estimates, causing significant sell-offs in the US stock market, especially in the SOX index which dropped over 7%. Additionally, Intel, which announced a 15% staff reduction and suspension of dividends starting from Q4, saw a temporary drop of around 20% in after-hours trading. The domestic semiconductor industry is affected as well.
Shin-Bio Pharmaceutical is promoting the consideration and implementation of global clinical trials for its 2Q antiviral drug, SyB V-1901.
On the 1st, Shionogi & Co., Ltd. <4582> announced its consolidated financial results for the second quarter of the 2024 fiscal year (January-June 24), with revenue of 1.284 billion yen, a 59.6% decrease from the same period last year, an operating loss of 1.719 billion yen (compared to a loss of 0.049 billion yen in the same period last year), an ordinary loss of 1.481 billion yen (compared to a profit of 0.066 billion yen in the same period last year), and a net loss attributable to the parent company shareholders of 1.541 billion yen (compared to a loss of 0.079 billion yen in the same period last year). Currently, Torecan (R) infusion solution 100mg/4mL [RTD
Analysis
Price Target
No Data
No Data